S
ince the first description of acute respiratory distress syndrome (ARDS) in 1967 (1), the scientific community has strived to elucidate effective treatments for this clinical entity. Despite the extensive work that has emerged over decades, we continue to lack effective treatments for this syndrome. It continues to be associated with significant mortality, most recently estimated as high as 44% (2) . To date, the most widely accepted effective intervention with a significant impact on mortality is low tidal volume ventilation (3) . A category of therapies receiving recent attention is a group termed "rescue therapies," named such for their role in treating hypoxemia that is refractory to standard management strategies for ARDS. These include high-frequency oscillatory ventilation (HFOV), inhaled epoprostenol and nitric oxide, prone position ventilation, and extracorporeal membrane oxygenation (ECMO). Traditionally, these are interventions reserved for patients whose hypoxemia progresses despite recognition and treatment of ARDS. Intensivists generally agree that these different therapies rapidly improve oxygenation, but no clear consensus exists on whether or not they improve mortality (4) (5) (6) (7) .
Multiple large studies have been published recently, evaluating the use of these therapies in ARDS in earlier, "nonrescue" treatment algorithms. In February 2013, two large randomized controlled trials (RCTs) were published examining HFOV in ARDS. A study by Young et al (8) enrolled approximately 800 patients in the United Kingdom, and a study conducted by Ferguson et al (9) enrolled 571 patients in multiple centers worldwide. Neither trial found a benefit for HFOV in ARDS, and the second study suggested a possible increase in morality associated with early use of HFOV (8, 9) . Similarly, Guérin et al (10) evaluated prone position ventilation in a RCT that enrolled 466 patients with ARDS in France and Spain. The results of this trial were striking, with significant reduction in both 28-and 90-day mortality (10) .
Randomized studies, such as those recently published, evaluating interventions for the improvement of oxygenation, and ultimately mortality, provide insight into efficacy. However, one major limitation in the evidence exists: the interventions are applied via protocol to patients in the early phase of ARDS. These recent studies do not evaluate rescue therapies as traditionally used, and as a result, extrapolating the results to the routine clinical practice of using these treatments as rescue strategies for refractory hypoxemia becomes difficult. A study by Khandelwal et al (11) in this issue of Critical Care Medicine illustrates the challenge in evaluating rescue therapies for refractory hypoxemia, which fortunately is relatively rare, even in patients with ARDS. In this well-conducted, observational study of 428 patients with ARDS, the authors describe outcomes, including mortality, in patients who received rescue therapy, specifically inhaled epoprostenol, inhaled nitric oxide, and prone position ventilation, for refractory hypoxemia. Despite following these 428 patients for the duration of their critical illness, only 62 (15%) developed refractory hypoxemia and received some form of rescue therapy. For their primary outcome, the authors found a significant increase in overall mortality associated with the use of rescue therapies, a difference which was observed for in-hospital mortality as well. The timing and use of rescue therapy in this study were not randomized but instead implemented and managed at the discretion of the primary team. This selection bias confounds the finding of increased mortality as sicker patients are not only more likely to receive rescue therapies from their primary team but also more likely to die. Unfortunately, this may represent an inherent limitation of studying rescue therapies as conducting randomized trials designed with adequate power to detect clinically relevant differences in these patients remains difficult, if not impossible.
The use of rescue therapies brings many challenges, including practical limitations. The authors recognize this point and performed a cost analysis to help determine the utility of rescue therapies in the clinical setting. The authors were not able to detect a difference in cost although the analysis was limited by a small sample size. Regardless, this article raises the question of whether we should rethink how we use rescue therapies going forward. With recent studies evaluating various rescue therapies in early ARDS as part of standardized protocols, clinicians should consider taking a more objective and potentially earlier approach in applying rescue measures, potentially moving them from the "rescue" part of clinical practice toward the more routine. Also, it would be ideal to have further evidence supporting the use of less practical therapies, such as HFOV and prone positioning, as rescue modalities in select groups of patients. Khandelwal et al (11) A s up to one third of the United States adult population is considered to be obese or morbidly obese, defined as a body mass index (BMI) more than or equal to 30, the impact of obesity on outcomes in both the trauma and critical care populations needs to be constantly examined and healthcare tailored to meet this major comorbidity (1) (2) (3) (4) (5) . Ditillo et al (1) in a publication in 2014 looked at the largest administrative trauma database globally, the National Trauma Data Bank, and found that obesity was an independent risk factor for adverse outcomes in the blunt trauma population. Shashaty et al (6) also found obesity to be an independent predictor of acute kidney injury (AKI) in the critically injured trauma patient.
Obesity in and of itself as a predictor for AKI makes sense within this patient population. Numerous studies have shown that in times of stress, adipose tissue releases multiple inflammatory mediators, including interleukin-6, which can result in AKI. Furthermore, the relationship between adipose tissue and the renin-angiotensin system has been well documented and would make renal dysfunction in obese trauma patients predictable. Increased adiposity may also result in a subtle component of abdominal compartment syndrome-or, at the very least, increased intra-abdominal pressure-which can result in a certain level of renal hypoperfusion, again predisposing these patients to AKI. Obese patients tend to have more comorbid conditions, including hypertension and atherosclerosis, which may yield subtle baseline renal dysfunction (7) .
Yet, what is novel about the article by Shashaty et al (8) in this issue of Critical Care Medicine, and what the authors should be congratulated for, is their attempt-and success-at devising an excellent and reproducible means of not so much defining obesity but rather reproducibly measuring and hence defining adiposity based on the trauma CT scan. Utilizing adiposity as a surrogate for obesity, the authors were able to show a clear link between obesity and AKI. This may seem like a relatively benign finding, yet in order to understand the true merits of this article, one must attempt to explain why the literature has shown discrepant results when using obesity as a predictor for adverse outcomes in critically injured trauma patients.
results to the different types of rescue therapies, but due to insufficient number of patients, observational study design, and exclusion of other rescue therapies, namely, HFOV and ECMO, the results are unable to effectively comment on the superiority of any given therapy. Ideally, a future study providing clinicians with guidance for rescue therapies will include multiple centers worldwide, focus evaluation on patients with refractory hypoxemia, include objective inclusion criteria, and follow clear protocols on the timing and application of a given therapy. An ideal trial would also evaluate the practical aspects of implementing the rescue therapy in addition to measuring its clinical impact.
